<DOC>
	<DOCNO>NCT00003642</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug combine radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness radiation therapy combine fluorouracil cisplatin treat patient stage II stage III bladder cancer , undergone transurethral resection .</brief_summary>
	<brief_title>Radiation Therapy Chemotherapy Following Surgery Treating Patients With Stage II Stage III Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate rate severe acute toxicity occur therapy accelerate external radiotherapy concurrent fluorouracil ( 5-FU ) cisplatin follow transurethral resection bladder patient stage II III muscle invasive transitional cell carcinoma bladder . II . Evaluate rate freedom local recurrence combine therapy assess 3 month end treatment patient . III . Assess feasibility new therapeutic approach patient population . IV . Determine overall recurrent free survival , long term side effect , overall survival patient . OUTLINE : This open label , multicenter study . Patients undergo accelerate external radiotherapy twice daily 5 day week 5 week . Concurrent chemotherapy administer first fifth week consist cisplatin IV 2 hour daily fluorouracil 24 hour continuous infusion daily day 1-5 . Patients follow 3 month , every 3 month first 2 year , every 6 month thereafter . PROJECTED ACCRUAL : There 19-43 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unifocal multifocal transitional cell carcinoma bladder great 5 cm , evidence muscle invasion document transurethral resection bladder ( TURB ) , residual visible palpable tumor mass end TURB Stage II III ( T2T3 , N0 , M0 ) No squamous cell adenocarcinoma No evidence pelvic lymph node involvement CT scan MRI No evidence hydronephrosis No evidence distant metastases No disease prostatic urethra PATIENT CHARACTERISTICS : Age : Under 76 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 11 g/dL Hepatic : Not specify Renal : See Disease Characteristics Creatinine clearance great 50 mL/min Cardiovascular : No progressive ischemic cardiopathy Other : No reduced bladder capacity No prior concurrent malignancy except basal cell carcinoma carcinoma situ cervix treat hysterectomy PRIOR CONCURRENT THERAPY : Biologic therapy : Prior immunotherapy superficial disease allow No concurrent growth factor Chemotherapy : No prior systemic chemotherapy Prior intravesical chemotherapy intravesical BCG allow Endocrine therapy : Not specify Radiotherapy : No prior pelvic radiotherapy Surgery : No prior surgery bladder cancer except transurethral resection bladder</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>